Skip to content
value.today

Daré Bioscience, Inc.

DARE
$13 Mmarket cap on Oct 28, 2026-62.9% since Jan 2024
Compare
World rank
#25,464
Revenue
$1 M
For year ending December-2025
Net income
$-13 M
-1301.0% margin
SEC filing
Employees
24
As of March 25, 2026
SEC filing

Daré Bioscience, Inc. in brief

Daré Bioscience, Inc. is a listed company in the Biotechnology industry, based in San Diego, California, USA. Its market value was $13 M on 28 October 2026, which makes it the 25,464th largest listed company in the world and the 4,240th largest in the USA on this site. In the year to December 2025 it had sales of $1 M and a net loss of $13 M. It employs about 24 people. Its largest product and service lines by sales in 2025 were License fee revenue and other revenue (100%). Its shares trade under the symbol DARE (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Daré Bioscience, Inc.

We are a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions. Every innovation we advance is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, pelvic pain to fertility, vaginal health to infectious disease, we’re working to close critical gaps in care using science that serves her needs.

For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline.

From the company's annual report filed with the US SEC: read the report

Daré Bioscience, Inc. timeline

4 events, 2007–2017
  1. 2007
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2008
  4. ✎
    Renamed Cerulean Pharma Inc.
    Formerly Tempo Pharmaceuticals Inc.
  5. 2014
  6. 🔔
    Initial public offering as Cerulean Pharma Inc.
    Final prospectus filed with the SEC on 14 April 2014; shares registered for exchange trading on 4 April 2014.
  7. 2017
  8. ✎
    Renamed Dare Bioscience, Inc.
    Formerly Cerulean Pharma Inc..

Events of Daré Bioscience, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$20 M$40 M$60 M$80 M2023202420252026

World rank over time

▼ down 2,292 places since 2022
2022-12-25: #23179#23,17920222023-07-30: #23929#23,92920232024-01-05: #26556#26,55620242026-03-08: #11987#11,98720262026-08-01: #22496#22,49620262026-10-13: #25660#25,66020262026-10-28: #25471#25,4712026

Rank in USA: #4,505 (Dec 2022) · #4,563 (Jul 2023) · #4,206 (Jan 2024) · #2,301 (Mar 2026) · #3,998 (Aug 2026) · #4,220 (Oct 2026) · #4,242 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
12.6×
Price / book
4.6×
Free cash flow yield
-79.2%
Net margin
-1301.0%
Operating margin
-1315.5%
Return on equity
-471.8%
Liabilities / assets
91.3%
Revenue growth
+10200.0%
R&D / revenue
535.9%
Revenue per employee
$43 K
Profit per employee
$-558 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-17M—FY18Fiscal year ending Dec 2019: revenue —, net income $-14M—FY19Fiscal year ending Dec 2020: revenue —, net income $-27M—FY20Fiscal year ending Dec 2021: revenue —, net income $-39M—FY21Fiscal year ending Dec 2022: revenue $10M, net income $-31M$10MFY22Fiscal year ending Dec 2023: revenue $3M, net income $-30M$3MFY23Fiscal year ending Dec 2024: revenue $0M, net income $-4M$0MFY24Fiscal year ending Dec 2025: revenue $1M, net income $-13M$1MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$1M+10200.0%$-14M$-13M-1301.0%
Dec 2024$0M-99.6%$-23M$-4M-40500.0%
Dec 2023$3M-71.9%$-31M$-30M-1073.3%
Dec 2022$10M—$-31M$-31M-309.5%
Dec 2021——$-39M$-39M—
Dec 2020——$-27M$-27M—
Dec 2019——$-14M$-14M—
Dec 2018——$-17M$-17M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-10M$0M$-10M$-1.20—
Dec 2024$5M$1M$5M$-0.48—
Dec 2023$-39M$1M$-39M$-4.15—
Dec 2022$-18M$0M$-18M$-0.37—
Dec 2021$-29M$0M$-29M$-0.63—
Dec 2020$-25M$0M$-25M$-0.91—
Dec 2019$-13M$0M$-13M$-0.97—
Dec 2018$-10M$0M$-10M$-1.57—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024: revenue $0M, net income $-5M$0MSep ’24Three months to Dec 2024 (from the annual report): revenue —, net income $-6M—Dec ’24Three months to Mar 2025: revenue $0M, net income $-4M$0MMar ’25Three months to Jun 2025: revenue —, net income $-4M—Jun ’25Three months to Sep 2025: revenue $0M, net income $-4M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-1M—Dec ’25Three months to Mar 2026: revenue $0M, net income $-3M$0MMar ’26Three months to Jun 2026: revenue $0M, net income $-3M$0MJun ’26

Latest quarter to Jun 2026: revenue $0M, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Daré Bioscience, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$1 M
Operating income
$-14 M
Net income
$-13 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$32 M
Total liabilities
$30 M
Total equity
$3 M

As of December-2025

Top 37 institutional investors in Daré Bioscience, Inc.#

As of Sep 30, 2026
37 institutions held 1.7 M shares (about 11.4% of the shares outstanding) on Sep 30, 2026. The ten largest hold 10.2%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Daré Bioscience, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC632,871-8,006 (-1.25%)4.14%$1 MNov 13, 2026
2UBS Group AG239,597+232,787 (+3418.31%)1.57%$0 MNov 10, 2026
3US Bancorp \de\220,920+100,000 (+82.70%)1.44%$0 MNov 5, 2026
4Geode Capital Management, LLC152,405+12,312 (+8.79%)1.00%$0 MNov 6, 2026
5Vanguard Fiduciary Trust Co91,2690 (0.00%)0.60%$0 MNov 13, 2026
6BlackRock, Inc.62,162-2,086 (-3.25%)0.41%$0 MNov 13, 2026
7State Street Corp47,4150 (0.00%)0.31%$0 MNov 12, 2026
8Citadel Advisors LLC45,142New0.30%$0 MNov 16, 2026
9XTX Topco Ltd37,376New0.24%$0 MNov 16, 2026
10HRT Financial LP37,342+14,912 (+66.48%)0.24%$0 MNov 13, 2026
11Northern Trust Corp34,2090 (0.00%)0.22%$0 MNov 16, 2026
12Virtu Financial LLC33,506+17,703 (+112.02%)0.22%$0 MNov 17, 2026
13Two Sigma Securities, LLC19,656New0.13%$0 MNov 16, 2026
14Garde Capital, Inc.16,220New0.11%$0 MOct 29, 2026
15LPL Financial LLC14,8890 (0.00%)0.10%$0 MNov 6, 2026
16Raymond James Financial Inc14,628-236 (-1.59%)0.10%$0 MNov 12, 2026
17Price T Rowe Associates Inc /MD/13,3180 (0.00%)0.09%$0 MNov 16, 2026
18Objectivity Squared, LLC10,9150 (0.00%)0.07%$0 MNov 12, 2026
19Farther Finance Advisors, LLC9,408-42 (-0.44%)0.06%$0 MOct 8, 2026
20Vanguard Global Advisers, LLC2,9400 (0.00%)0.02%$0 MNov 13, 2026
21Tower Research Capital LLC (TRC)1,733New0.01%$0 MNov 16, 2026
22PNC Financial Services Group, Inc.1,100New0.01%$0 MNov 6, 2026
23IFS Advisors, LLC9500 (0.00%)0.01%$0 MOct 14, 2026
24SBI Securities Co., Ltd.715+70 (+10.85%)0.00%$0 MOct 22, 2026
25Royal Bank Of Canada596New0.00%$0 MNov 16, 2026
Show all 37: investors 26 to 37
Institutional investors 26 to 37 in Daré Bioscience, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Entrust Financial LLC500New0.00%$0 MNov 4, 2026
27Jacobi Capital Management LLC434New0.00%$0 MNov 5, 2026
28Jones Financial Companies Lllp3960 (0.00%)0.00%$0 MNov 13, 2026
29Keating Financial Advisory Services, Inc.107New0.00%$0 MNov 12, 2026
30Caldwell Sutter Capital, Inc.1000 (0.00%)0.00%$0 MNov 9, 2026
31Mather Group, LLC.840 (0.00%)0.00%$0 MOct 14, 2026
32Jpmorgan Chase & Co19New0.00%$0 MNov 12, 2026
33Inspire Investing, LLC140 (0.00%)0.00%$0 MOct 22, 2026
34FMR LLC6New0.00%$0 MNov 10, 2026
35Compass Financial Management LLC5New0.00%$0 MOct 30, 2026
36Barclays PLC2-246 (-99.19%)0.00%$0 MNov 6, 2026
37Putney Financial Group LLC1New0.00%$0 MOct 30, 2026

Mutual funds holding Daré Bioscience, Inc.#

10 funds hold shares worth $2 M (about 5.4% of the company). Since their previous reports 7 added shares and 2 sold, buying $1 M net.
Mutual funds holding Daré Bioscience, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.471,486$1 M3.1%<0.01%+90%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.161,385$0 M1.1%<0.01%−25%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC78,050$0 M0.51%<0.01%+6.3%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors45,289$0 M0.30%<0.01%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC32,473$0 M0.21%<0.01%+149%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC15,326$0 M0.10%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC7,571$0 M0.05%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.8,006$0 M0.05%<0.01%newJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC2,978$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC626$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Daré Bioscience, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
25
since
Daré Bioscience, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Susan L. KelleyDirectorGrant or award+23,696——23,696Form 4
filed Gregory W. MatzDirectorGrant or award+30,805——30,847Form 4
filed William H. RastetterDirectorGrant or award+38,862——39,721Form 4
filed Jessica D. GrossmanDirectorGrant or award+26,066——26,066Form 4
filed Robin Joan SteeleDirectorGrant or award+26,540——47,055Form 4
filed Roger HawleyDirectorBuyindirect+454,545$1.100$500 K944,956Form 4
filed Roger HawleyDirectorBuy+140,000$1.450$203 K140,000Form 4
filed Sabrina Martucci JohnsonChief Executive Officer, Director, 10% ownerGrant or awardindirect+962,062——962,062Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Daré Bioscience, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
986,092
6.8% of shares · 6.07 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-12 reverse split ; 1-for-10 reverse split in the period to ; 1-for-10 reverse split ; 14.507-for-1 split

Trading halts

  • 2026-08-14 16:45 UTC, code LUDP, resumed 16:50 UTC

Fails to deliver

  • : 2,356 shares at $0.66
  • : 5,262 shares at $0.65
  • : 12,798 shares at $0.69
  • : 9,326 shares at $0.69
  • : 314 shares at $0.73

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Daré Bioscience, Inc. scorecard#

Passes 2 of the 13 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median4.6×Price to book 4.6× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median12.6×Price to sales 12.6× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-79.2%Free cash flow is -79.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.20 vs -0.48Diluted EPS -1.20 in fiscal 2025 against -0.48 the year before (report's currency).
    • ✓Net income higher than five years earlier-$13 M-$13 M in fiscal 2025 against -$27 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$13 MNet income -$13 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities1.1×Current ratio 1.14 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-9.09Z-score -9.09 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year31.6%Diluted shares up 31.6% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Daré Bioscience, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Daré Bioscience, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue1.00.02.8100————0.8
Cost of revenue0.30————————
Research and development5.514r223031218.56.41.00.1r
Selling, general and administrative8.89.2————————
General and administrative—9.212118.46.55.34.72.70.2r
Operating expenses1423344139271417110.6r
Operating income−14−23−31−31−39−27−14−17−11−0.6
Interest and finance income—————————0.1
Interest expense and finance costs————————0.30.0r
Other non-operating income (expense)−0.21.0r0.80.40.00.00.10.1−0.3−2.2
Income before tax−14−4.1−30−31−39−27−14−17−12−0.7
Income tax00000000.00—
Net income attributable to shareholders−13−4.1−30−31−39−27−14−17−12−0.7r
Earnings per share, basic-1.20-0.48-4.15r-0.37-0.63-0.91-0.97-1.57r3.56r-0.81r
Earnings per share, diluted-1.20-0.48-4.15r-0.37-0.63-0.91-0.97-1.57r3.56r-0.81r
Shares, weighted average (basic)118.57.3r856130——3.20.8
Shares, weighted average (diluted)118.57.3r85613016113.20.8r
Balance sheet
Cash and cash equivalents25161035524.74.86.87.60.0r
Receivables————0————0.8
Other current assets0.6000———00.21.0
Current assets27181843557.06.47.28.30.0r
Property, plant and equipment1.61.30.70.10.00.00.10.000.7
Right-of-use (leased) assets1.11.21.30.5r——————
Goodwill———————05.2r—
Total assets32222144567.67.47.8140.0r
Accounts payable1.21.53.42.02.11.01.10.50.3r1.4
Debt due within a year—0.0r————————
Current liabilities2422r2032167.75.61.11.00.8r
Lease liabilities (non-current)0.60.80.90.100.0r0.40.4——
Non-current liabilities—————————7.6
Total liabilities30282633178.77.01.11.00.8
Retained earnings−189−175−171−141−110−71−44−29−12−0.7r
Shareholders' equity2.8−6.0−5.01139−1.20.46.713r−0.7r
Total liabilities and equity32222144567.67.47.8140.0r
Shares outstanding148.78.3r85844220116.00.9r
Cash-flow statement
Depreciation and amortization1.60.0———————0.3
Share-based compensation1.52.22.52.21.60.70.50.10.00.0r
Cash from operating activities−9.95.5r−39−18−29−25−13−10−2.5−0.4r
Capital expenditure−0.4−0.6−0.6−0.1−0.0−0.00−0.00−0.5
Cash from investing activities−0.4−0.6−0.6−0.1−0.0−0.06.1−0.59.9−0.4
Shares issued210.5—1.316235.2——0.9
Cash from financing activities190.4r161.376255.2100.20.2r
Exchange-rate effect on cash0.0−0.1−0.0−0.2−0.10.0−0.0−0.1——
Change in cash9.05.2r−24−1747−0.1−2.0−0.87.5−0.2r
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Daré Bioscience, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • License fee revenue and other revenue$1 M100%

Business segments

  • Reportable$1 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Daré Bioscience, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 4 subsidiaries on file.

Daré Bioscience, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office3 subsidiaries—
🇦🇺 Australia1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Events at Daré Bioscience, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Directors and officers 2 · Material agreement 1 · Agreement ended 1 · Unregistered share sale 8 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 5

Daré Bioscience, Inc.: events reported to the SEC
FiledWhat happenedFiling
Shareholder vote8-K
Delisting notice8-K
Bylaws or fiscal year changed8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Delisting notice8-K
Directors and officersShareholder vote8-K
Unregistered share sale8-K
Results announced8-K
Unregistered share sale8-K
Unregistered share sale8-K
Directors and officers8-K
Unregistered share sale8-K
Results announced8-K
Unregistered share sale8-K
Unregistered share sale8-K
Unregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Agreement ended8-K
Results announced8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

6 private funding rounds before listing

Private share sales · funding history

Private share sales of Daré Bioscience, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2026$12 MPrivate placement after listing$10 to $50 million12optionsSEC
Dec 2023$2 MPrivate placement after listingUnder $2 million1optionsSEC
Nov 2019$4 MPrivate placement after listing$2 to $10 million28equitySEC
Jul 2017$21 MPrivate placement after listing$10 to $50 million18equity, optionsSEC
Nov 2012$13 MNo. 6$10 to $50 million16equitySEC
Dec 2011$15 MNo. 5$10 to $50 million19equity, optionsSEC
Nov 2010$17 MNo. 4$10 to $50 million17equitySEC
Sep 2010$2 MNo. 3Under $2 million15debt, optionsSEC
May 2010$5 MNo. 2$2 to $10 million13debt, optionsSEC
Jul 2009$10 MNo. 1$10 to $50 million13equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Government contracts: Daré Bioscience, Inc.#

No federal contracts in fiscal 2025, and $2.0 M in grants.

Contracts, FY2025
$0
Grants, FY2025
$2.0 M
FY2027 to date
—
contracts and grants
Since FY2008
$3.7 M
contracts and grants
Daré Bioscience, Inc.: federal obligations by fiscal year
Fiscal yearContractsGrants
FY2025$0$2.0 M
FY2024$0$960 K
FY2023$0$385 K
FY2021$0$310 K

Source: USAspending.gov. Obligations are binding promises to pay, not payments, and can be negative when an award is cut. Counted under Daré Bioscience, Inc.: DARE BIOSCIENCE, INC. (UEI UC4EFLZHANH4)

H-1B hiring at Daré Bioscience, Inc.#

1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $99 K a year.

Certified, FY2025
1
#1,968 among companies on value.today
Worker positions
1
Median wage offered
$99 K
a year, full-time
Applications filed
1
Daré Bioscience, Inc.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
Senior AccountantAccountants and Auditors1$99 K

Where: San Diego, CA 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Dare Bioscience, Inc.

How Daré Bioscience, Inc. compares in Biotechnology

  • Market cap$13 M · higher than 13% of 726
  • Revenue$1 M · higher than 25% of 647
  • Price / sales12.6× · lower than 38% of 339
  • Price / book4.6× · lower than 33% of 534
  • FCF yield-79.2% · higher than 13% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Daré Bioscience, Inc.🇺🇸$13 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 25, 2026
Profile updated:
Nov 19, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Daré Bioscience, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Daré Bioscience, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Daré Bioscience, Inc.? Suggest a correction